|
|
Blood, 1 March 2006, Vol. 107, No. 5, pp. 2123-2130.
Prepublished online as a Blood First Edition Paper on November 8, 2005; DOI 10.1182/blood-2005-08-3099.
 Previous Article | Next Article 
Submitted August 2, 2005
Accepted October 18, 2005
Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement
Richard P Hayhoe, Ahmad M Kamal, Egle Solito, Roderick J Flower, Dianne Cooper, and Mauro Perretti*
Centre for Biochemical Pharmacology, The William Harvey Research Institute, London, United Kingdom
Department of Cellular and Molecular Neuroscience, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom
* Corresponding author; email: m.perretti{at}qmul.ac.uk.
We have tested the effects of annexin 1 (ANXA1) and its N-terminal peptide Ac2-26 on PMN recruitment under flow. Differential effects of the full-length protein and its peptide were observed; ANXA1 inhibited firm adhesion of human PMN, whilst Ac2-26 significantly attenuated capture and rolling without effect on firm adhesion. Analysis of the effects of ANXA1 and Ac2-26 on PMN adhesion molecule expression supported the flow chamber results, with Ac2-26 but not ANXA1 causing L-selectin and PSGL-1 shedding. ANXA1 and its peptide act via the FPR family of receptors. This was corroborated using HEK-293 cells transfected with FPR or FPRL-1/ALX (the two members of this family expressed by human PMN). While Ac2-26 bound both FPR and FPRL-1/ALX, ANXA1 bound FPRL-1/ALX only. ANXA1 and Ac2-26 acted as genuine agonists; Ac2-26 binding led to ERK activation in both FPR and FPRL-1/ALX transfected cells while ANXA1 caused ERK activation only in cells transfected with FPRL-1/ALX. Finally blockade of FPRL-1/ALX with a neutralising monoclonal antibody was found to abrogate the effects of ANXA1 in the flow chamber but was without effect on Ac2-26-mediated inhibition of rolling. These findings demonstrate for the first time distinct mechanisms of action for ANXA1 and its N-terminal peptide Ac2-26.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Putting the brakes on neutrophils
- Charles N. Serhan and Nan Chiang
Blood 2006 107: 1742-1743.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
D. Cooper, L. V. Norling, and M. Perretti
Novel insights into the inhibitory effects of Galectin-1 on neutrophil recruitment under flow
J. Leukoc. Biol.,
June 1, 2008;
83(6):
1459 - 1466.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yona, H.-H. Lin, P. Dri, J. Q. Davies, R. P. G. Hayhoe, S. M. Lewis, S. E. M. Heinsbroek, K. A. Brown, M. Perretti, J. Hamann, et al.
Ligation of the adhesion-GPCR EMR2 regulates human neutrophil function
FASEB J,
March 1, 2008;
22(3):
741 - 751.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. V. Norling, A. L. F. Sampaio, D. Cooper, and M. Perretti
Inhibitory control of endothelial galectin-1 on in vitro and in vivo lymphocyte trafficking
FASEB J,
March 1, 2008;
22(3):
682 - 690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. R. Martin, M. Perretti, R. J. Flower, and J. L. Wallace
Annexin-1 modulates repair of gastric mucosal injury
Am J Physiol Gastrointest Liver Physiol,
March 1, 2008;
294(3):
G764 - G769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lange, D. J. Starrett, J. Goetsch, V. Gerke, and U. Rescher
Transcriptional profiling of human monocytes reveals complex changes in the expression pattern of inflammation-related genes in response to the annexin A1-derived peptide Ac1-25
J. Leukoc. Biol.,
December 1, 2007;
82(6):
1592 - 1604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. N. E. Gavins, J. Dalli, R. J. Flower, D. N. Granger, and M. Perretti
Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculation
FASEB J,
June 1, 2007;
21(8):
1751 - 1758.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Urquhart, G. Rosignoli, D. Cooper, R. Motterlini, and M. Perretti
Carbon Monoxide-Releasing Molecules Modulate Leukocyte-Endothelial Interactions under Flow
J. Pharmacol. Exp. Ther.,
May 1, 2007;
321(2):
656 - 662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Scannell, M. B. Flanagan, A. deStefani, K. J. Wynne, G. Cagney, C. Godson, and P. Maderna
Annexin-1 and Peptide Derivatives Are Released by Apoptotic Cells and Stimulate Phagocytosis of Apoptotic Neutrophils by Macrophages
J. Immunol.,
April 1, 2007;
178(7):
4595 - 4605.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. John, V. Sahni, D. Mehet, J. F. Morris, H. C. Christian, M. Perretti, R. J. Flower, E. Solito, and J. C. Buckingham
Formyl peptide receptors and the regulation of ACTH secretion: targets for annexin A1, lipoxins, and bacterial peptides
FASEB J,
April 1, 2007;
21(4):
1037 - 1046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. D'Acquisto, A. Merghani, E. Lecona, G. Rosignoli, K. Raza, C. D. Buckley, R. J. Flower, and M. Perretti
Annexin-1 modulates T-cell activation and differentiation
Blood,
February 1, 2007;
109(3):
1095 - 1102.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. H. Yang, M.-L. Toh, C. D. Clyne, M. Leech, D. Aeberli, J. Xue, A. Dacumos, L. Sharma, and E. F. Morand
Annexin 1 Negatively Regulates IL-6 Expression via Effects on p38 MAPK and MAPK Phosphatase-1
J. Immunol.,
December 1, 2006;
177(11):
8148 - 8153.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Chiang, C. N. Serhan, S.-E. Dahlen, J. M. Drazen, D. W. P. Hay, G. E. Rovati, T. Shimizu, T. Yokomizo, and C. Brink
The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo
Pharmacol. Rev.,
September 1, 2006;
58(3):
463 - 487.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Babbin, W. Y. Lee, C. A. Parkos, L. M. Winfree, A. Akyildiz, M. Perretti, and A. Nusrat
Annexin I Regulates SKCO-15 Cell Invasion by Signaling through Formyl Peptide Receptors
J. Biol. Chem.,
July 14, 2006;
281(28):
19588 - 19599.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
